peptideInjectableNot FDA-approvedResearch chemicalNever approved by the FDA or EMA; development was discontinued after the cited trialsSold only as a research chemical, not as a dietary supplement
CJC-1295 with DACBenefits, Dosage & Interactions
Also known as: CJC-1295 DAC, Modified GRF
CJC-1295 with DAC (Drug Affinity Complex) is a synthetic analog of growth hormone-releasing hormone (GHRH). It is also known as Modified GRF 1-29 with DAC. Research on CJC-1295 with DAC focuses on muscle and strength, tissue recovery, and healthy aging.
Researched by DoseRoutine R&D TeamReviewed for accuracy by Nicholas Alexander, RSELast updated
Evidence: Moderate — One published human randomized trial; results not yet replicated.
Evidence strengthModerate · 3/4
PreclinicalStrong human evidence
One published human randomized trial; results not yet replicated.
Plasma half-life
~8 days
Default unit
mcg
What published protocols report
Ranges documented in the literature, shown for reference. DoseRoutine does not recommend an amount — your prescriber or the product label sets the dose.
- Reported amounts
- The healthy-adult trial tested single and repeated doses from 30 to 240 micrograms/kg subcutaneously; sustained GH/IGF-1 elevation was reported at 60 to 90 micrograms/kg given every 7 to 14 days[1][2]
- Cycle length
- The cited trial dosed subjects for up to 3 injections over a month; longer-term human data were not identified[1][2]
Reported for CJC-1295 with DAC in the cited sources. Published ranges are not dosing advice.
References & evidence
Documents the CJC-1295 with DAC entry is written from. Each number matches an inline marker above.
- [1]Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adultsTeichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA · The Journal of Clinical Endocrinology & Metabolism · 2006 · Peer-reviewed · PMID 16352683
- [2]Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjectsSackmann-Sala L, Ding J, Frohman LA, Kopchick JJ · Growth Hormone & IGF Research · 2009 · Peer-reviewed · PMID 19386527
How to track CJC-1295 with DAC doses
CJC-1295 with DAC is tracked as a protocol rather than a single reminder: a vial with a concentration, a schedule that may be titrated or cycled, and a rotation of injection sites. Here is the record that keeps all three consistent.
- 1
Record the vial and concentration
Log the vial strength and the volume of bacteriostatic water you added so CJC-1295 with DAC is stored as a concentration rather than a guess. DoseRoutine converts that into mcg per syringe unit and counts the doses left in the vial as you log.
- 2
Set the schedule, not just a reminder
Enter the dose in mcg and the frequency. Cycled protocols get a start and end date so the history stays accurate when CJC-1295 with DAC comes out of the routine.
- 3
Rotate and log the injection site
Pick the site at the moment you log the dose. The site map shows what you used last and how recently, which is the part that drifts fastest when two compounds run on different frequencies.
- 4
Log adherence, not intentions
Mark each dose taken, skipped or delayed as it happens. Weeks of honest logs are what make an adherence rate or a trend line meaningful; retrospective guessing is not.
- 5
Review against outcomes
With a reported half-life around 192 h, effects and timing shifts show up over days rather than instantly. Review CJC-1295 with DAC alongside your logged metrics and any relevant blood work every few weeks before changing the dose.
What to log each time
- Dose in mcg and the syringe units it worked out to
- Vial: reconstitution date, concentration, doses remaining
- Injection site and time
- Any side effects in the 24 h after the dose
References & Evidence
Sources on this page that document CJC-1295 with DAC dosing, timing and safety.
- [1]National Center for Biotechnology Information View source
Educational information only — not medical advice. Dose ranges vary by person, indication and prescriber.
What is CJC-1295 with DAC studied for?
What is CJC-1295 with DAC?Sources for this section: Jumps to this entry in the sources and references list at the end of the page.
CJC-1295 with DAC (Drug Affinity Complex) is a synthetic analog of growth hormone-releasing hormone (GHRH). It is also known as Modified GRF 1-29 with DAC. This peptide is designed to stimulate the pituitary gland to release growth hormone (GH) in a pulsatile manner, mimicking the body's natural GH secretion pattern. The 'DAC' component significantly extends its half-life, allowing for less frequent administration compared to GHRH analogs without DAC. The primary interest in CJC-1295 with DAC centers on its potential to increase GH and insulin-like growth factor 1 (IGF-1) levels, which are associated with various physiological processes including muscle growth, fat reduction, and recovery. Its application is primarily in research and investigational contexts, with proponents citing potential benefits for body composition and regenerative processes. It is administered via subcutaneous injection.
CJC-1295 with DAC is not approved by regulatory bodies like the FDA for human use. Its use in humans is considered investigational and off-label, with limited clinical trial data available to support its efficacy and safety for specific medical conditions.
What does the research say about CJC-1295 with DAC?
Tap a section to expand.
CJC-1295 with DAC acts as a growth hormone-releasing hormone (GHRH) mimetic. It selectively binds to and activates the GHRH receptor in the anterior pituitary gland. Activation of this receptor leads to the release of growth hormone (GH) from somatotroph cells into the bloodstream. Unlike administering exogenous GH directly, CJC-1295 with DAC encourages the body's own pituitary gland to produce and release GH. This mechanism theoretically maintains the pulsatile nature of GH secretion, which is considered more physiological than a constant infusion of GH. The 'DAC' (Drug Affinity Complex) component is an albumin-binding moiety. When CJC-1295 is formulated with DAC, it binds reversibly to albumin in the blood. This binding protects the peptide from enzymatic degradation and reduces its renal clearance, thereby significantly extending its half-life. This extended half-life allows the peptide to continuously stimulate the pituitary gland over a longer period, leading to sustained increases in GH and subsequently, insulin-like growth factor 1 (IGF-1) levels. The increase in GH and IGF-1 are thought to mediate the downstream effects attributed to CJC-1295 with DAC, such as anabolic effects on muscle and bone, and lipolytic effects on fat tissue. (Source: PubChem, DrugBank)
Source for this section: Sources for How does CJC-1295 with DAC work?: Jumps to this entry in the sources and references list at the end of the page.
The potential benefits of CJC-1295 with DAC are primarily extrapolated from its ability to increase growth hormone (GH) and insulin-like growth factor 1 (IGF-1) levels. These elevated levels are associated with a range of physiological effects:
* **Muscle Growth and Strength:** Increased GH and IGF-1 are known to promote protein synthesis and cellular proliferation, which can contribute to muscle hypertrophy and enhanced strength. This is a primary area of interest for individuals in bodybuilding and athletic communities.
* **Fat Loss:** Growth hormone has lipolytic properties, meaning it can promote the breakdown of fat cells and reduce adipose tissue. Increased GH levels induced by CJC-1295 with DAC may therefore contribute to body fat reduction.
* **Improved Recovery:** GH and IGF-1 play roles in tissue repair and regeneration. Enhanced levels might aid in faster recovery from exercise, injury, and general wear and tear, potentially reducing downtime for athletes.
* **Bone Density:** IGF-1 is involved in bone metabolism and density. Increased levels could potentially support bone health, although direct clinical evidence for CJC-1295 with DAC specifically is limited.
* **Anti-Aging and Longevity:** While often discussed in anti-aging contexts, robust clinical evidence directly linking CJC-1295 with DAC to increased longevity or significant anti-aging effects in humans is lacking. The hypothesis stems from the known role of GH in maintaining youthful body composition and tissue function.
It is crucial to note that while these benefits are theoretically plausible based on the known effects of GH and IGF-1, comprehensive and long-term clinical trials specifically on CJC-1295 with DAC in humans are limited. Therefore, these potential benefits are largely based on anecdotal reports, in vitro studies, and animal research rather than conclusive human clinical data. (Source: DrugBank, various research abstracts via PubMed for GH/IGF-1 effects)
Evidence for CJC-1295 with DAC primarily stems from early clinical trials and preclinical studies, alongside extensive anecdotal accounts from research chemical communities. A key study published in the Journal of Clinical Endocrinology & Metabolism (2006) investigated the pharmacokinetics and pharmacodynamics of CJC-1295 (without DAC) and CJC-1295 with DAC in healthy adults. This study notably demonstrated that CJC-1295 with DAC resulted in sustained, dose-dependent increases in plasma GH and IGF-I levels for up to 14 days after a single injection, significantly extending the half-life compared to GHRH without DAC. It confirmed the mechanism of action by showing that it acted on the pituitary to increase pulsatile GH secretion. (Source: Journal of Clinical Endocrinology & Metabolism, 2006; 91(3): 839–847 - accessible via PubMed).
Further research often involves _in vitro_ and animal models exploring its impact on muscle growth, fat metabolism, and tissue repair, aligning with the known roles of GH and IGF-1. However, comprehensive, large-scale, placebo-controlled human clinical trials establishing the efficacy and safety of CJC-1295 with DAC for specific medical conditions or performance enhancement are still limited. Much of the support for its claimed benefits comes from the understanding of growth hormone physiology rather than direct, dedicated studies on this specific peptide in clinical populations. As an unscheduled compound in many regions, human use is largely unofficial and without regulatory oversight, relying on self-reported outcomes. (Source: PubChem, DrugBank)
Side effects reported with CJC-1295 with DAC are generally consistent with those observed with elevated growth hormone (GH) and insulin-like growth factor 1 (IGF-1) levels, or common injection reactions. Potential side effects include:
* **Local Injection Site Reactions:** Redness, pain, itching, swelling, or irritation at the injection site.
* **Headache:** Mild to moderate headaches are commonly reported.
* **Nausea:** Some individuals may experience stomach upset or nausea.
* **Dizziness or Lightheadedness.**
* **Fluid Retention:** Can manifest as swelling in the hands, feet, or ankles, often described as a 'puffy' feeling.
* **Tingling or Numbness (Paresthesia):** Particularly in the extremities, a symptom sometimes associated with increased GH levels.
* **Increased Appetite.**
* **Flushing or Feeling of Warmth.**
* **Carpal Tunnel Syndrome:** In rare cases or with prolonged use at higher doses, elevated GH can contribute to symptoms of carpal tunnel syndrome.
* **Hypoglycemia (low blood sugar):** Although less common, GH can affect glucose metabolism, potentially leading to mild fluctuations. This is more relevant for individuals with pre-existing glucose regulation issues.
* **Suppression of Endogenous GH Release:** While designed to stimulate GH, chronic supraphysiological levels of exogenous GHRH analogs could, in theory, impact the body's natural feedback loops, though the pulsatile nature is intended to mitigate this.
Rare but serious concerns with long-term, unmonitored use of compounds that significantly elevate GH include potential effects on cardiovascular health, glucose metabolism (leading to insulin resistance or diabetes), and growth of existing tumors due to the mitogenic effects of IGF-1. However, these are often associated with sustained, very high levels of GH, typical of conditions like acromegaly, and are less well-studied in the context of CJC-1295 with DAC.
This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
CJC-1295 with DAC is an investigational peptide and is not approved by the FDA or other major regulatory bodies for human use. Its administration should be approached with caution due to limited long-term human safety data and a lack of standardized clinical guidelines. Key warnings include:
* **Unapproved Status:** As an unapproved compound, its purity, potency, and safety profile can vary significantly between suppliers, posing risks of contamination or incorrect dosing.
* **Potential for Undesirable GH/IGF-1 Levels:** While designed to increase GH and IGF-1, excessive or prolonged elevation, especially without medical supervision, can lead to adverse health outcomes similar to those observed in conditions like acromegaly. These include insulin resistance, glucose intolerance, hypertension, and joint pain.
* **Interaction with Glucose Metabolism:** Individuals with diabetes or pre-diabetes, or those prone to hypoglycemia, should exercise extreme caution, as elevated GH can influence blood sugar regulation.
* **Risk of Carcinogenesis:** Growth hormone and IGF-1 are mitogenic (promote cell division) and, theoretically, could accelerate the growth of existing undiagnosed tumors. While direct evidence linking CJC-1295 with DAC to increased cancer risk in healthy individuals is not robust, it remains a theoretical concern, particularly for those with a history of cancer.
* **Injection Safety:** As an injectable compound, proper sterile techniques are critical to prevent infections, abscesses, or other complications at the injection site.
* **Lack of Pediatric Data:** CJC-1295 with DAC is not indicated for use in children due to unknown effects on growth plates and development.
This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
Given its investigational status and effects on growth hormone (GH) and insulin-like growth factor 1 (IGF-1) levels, CJC-1295 with DAC is generally contraindicated in individuals with certain health conditions. These include:
* **Active Cancer or History of Cancer:** Due to the mitogenic (cell-proliferating) effects of GH and IGF-1, CJC-1295 with DAC is contraindicated in individuals with any active malignancy or a history of certain cancers, as it could potentially stimulate tumor growth.
* **Known Hypersensitivity:** Individuals with a known allergy or hypersensitivity to CJC-1295 with DAC or any of its excipients should not use it.
* **Acromegaly:** Patients with existing acromegaly (a condition of excessive GH production) should not use this compound, as it would further exacerbate their condition.
* **Diabetes Mellitus or Significant Insulin Resistance:** Due to its potential impact on glucose metabolism and insulin sensitivity, individuals with poorly controlled diabetes or severe insulin resistance should avoid CJC-1295 with DAC.
* **Pregnancy and Breastfeeding:** There is no safety data for CJC-1295 with DAC during pregnancy or lactation. Therefore, it is contraindicated in pregnant or breastfeeding women due to potential risks to the fetus or infant.
* **Children and Adolescents:** This peptide is not indicated for use in pediatric populations, as its effects on growing bodies, pubertal development, and long-term health are unknown and could be detrimental.
* **Untreated Hypothyroidism:** Adequate thyroid function is necessary for optimal GH production and response. Untreated hypothyroidism may blunt the effects of GHRH analogs and should be corrected before considering such compounds.
This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
Information on specific drug-drug interactions for CJC-1295 with DAC is limited due to its investigational status. However, based on its mechanism of action and effects on growth hormone (GH) and insulin-like growth factor 1 (IGF-1), general considerations for combinations should be noted:
* **Other Growth Hormone Secretagogues (GHSs) or Exogenous Growth Hormone (GH):** Combining CJC-1295 with DAC with other GHSs (e.g., ghrelin mimetics like Ipamorelin, MK-677) or exogenous GH could lead to excessively high GH and IGF-1 levels. This might increase the risk and severity of associated side effects such as fluid retention, glucose intolerance, carpal tunnel syndrome, and potential long-term health risks.
* **Insulin and Oral Hypoglycemic Agents:** Since GH can cause some degree of insulin resistance and affect blood glucose levels, individuals taking insulin or other medications for diabetes should use CJC-1295 with DAC with extreme caution. Dosage adjustments of antidiabetic medications may be necessary, and there is a risk of exacerbating glucose control issues.
* **Corticosteroids:** High doses of corticosteroids can suppress GH secretion and peripheral IGF-1 generation. This could theoretically reduce the efficacy of CJC-1295 with DAC.
* **Thyroid Hormones:** While not a direct contraindication for mixing, optimal thyroid function is important for GH action. Untreated hypothyroidism could diminish the effects of CJC-1295 with DAC. Ensuring euthyroid status is generally recommended.
* **Sex Hormones:** High doses of estrogen, especially oral forms, may decrease IGF-1 levels. Conversely, androgens can increase IGF-1. These interactions could modify the expected effects of CJC-1295 with DAC, though the clinical significance is not well-established.
Given the lack of comprehensive interaction studies, extreme caution is advised when considering combining CJC-1295 with DAC with any other medications or supplements. Any such decisions should be made under the guidance of a qualified healthcare professional.
This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
CJC-1295 with DAC has a very long half-life, approximately 168 hours (7 days), due to its Drug Affinity Complex (DAC) component. This extended half-life means that its effects on growth hormone (GH) and insulin-like growth factor 1 (IGF-1) are sustained over a prolonged period. Consequently, administration is typically infrequent, often once or twice per week rather than daily. The exact timing within the day is generally not considered critical, as the sustained release mechanism negates the need for precise daily timing to maximize pulsatile release. However, some users prefer evening/night-time administration, theorizing it might align more closely with the body's natural GH pulsatile release pattern which typically has a major pulse during deep sleep. There is no specific requirement related to food intake; it can be administered with or without food. User-directed dosage and timing must be set by a licensed clinician if prescribed.
Source for this section: Sources for When should you take CJC-1295 with DAC?: Jumps to this entry in the sources and references list at the end of the page.
What interacts with CJC-1295 with DAC?
| Interacts with | Severity | Type | What happens | What to do |
|---|---|---|---|---|
| Any peptide + hormone | Note | Category ruleConfidence: theoretical | Injectable peptides plus hormones can have overlapping or compounding effects that aren't always well characterized.Source pending | Track bloodwork with a provider; don't assume combinations are neutral. |
Frequently asked questions about CJC-1295 with DAC
CJC-1295 with DAC is a research peptide. It is also known as CJC-1295 DAC and Modified GRF. What follows is drawn from peer-reviewed literature indexed on PubMed, FDA label text where a label exists, and NIH reference records.
CJC-1295 with DAC is commonly discussed in the context of supporting muscle, recovery, and longevity. Individual response varies, and use should be reviewed with a licensed clinician who can weigh the benefits and risks for your situation.
For CJC-1295 with DAC, it is typically administered by injection, it is typically taken null, and its approximate half-life is 192 hours, which influences dosing frequency. Always follow the specific dose your clinician or the product label prescribes.
CJC-1295 with DAC carries potential side effects and drug interactions, documented in NIH, Mayo Clinic, and FDA label sources. Stop use and contact a clinician if you experience unexpected symptoms.
CJC-1295 with DAC is a peptide, and interactions are possible with prescriptions, hormones, peptides and other supplements in the same routine. With a reported plasma half-life near 192 hours, separating doses can change the picture as much as removing one. Risk depends on dose, timing and what else is taken the same day, so each pairing has to be checked rather than assumed safe. The free checker at https://doseroutine.com/interaction-checker covers CJC-1295 with DAC with no sign-up.
Combining a peptide like CJC-1295 with DAC with TRT is usually a question of labs rather than a blanket yes or no: the ester, injection interval and any aromatase inhibitor all change the answer. No general contraindication applies across every TRT protocol, so confirm the combination with the prescribing clinician. See the free TRT interaction reference: https://doseroutine.com/trt-supplement-interactions
Each peptide class carries its own profile against CJC-1295 with DAC: a healing peptide raises different questions than a GLP-1 agonist or a growth-hormone secretagogue. Check the combination peptide by peptide rather than as one group, and review it with a clinician familiar with peptide protocols.
A long plasma half-life of about 192 hours means CJC-1295 with DAC is commonly dosed every few days or weekly rather than daily. Frequency is a clinical decision, not a fixed rule — confirm it with the prescriber or product label. Comparison of apps that keep a schedule like this: https://doseroutine.com/best-dose-tracking-apps
With a plasma half-life near 192 hours, a single missed dose of CJC-1295 with DAC usually has a smaller effect on overall exposure than an irregular pattern of missed doses does. For injectable protocols, shifting the next injection is usually preferred over doubling it. Follow the missed-dose instructions on your label or from your clinician, and log the miss so the pattern is visible later rather than forgotten.
For an injectable like CJC-1295 with DAC the record needs more than a checkbox: vial concentration, the measured volume, and which site the last injection went into. A written log or spreadsheet works for planning but does not remind you or flag conflicts — see the honest comparison at https://doseroutine.com/vs/spreadsheet and the wider roundup at https://doseroutine.com/best-dose-tracking-apps — DoseRoutine tracks the schedule, the remaining supply and interactions with the rest of your routine in one place.
Sources cited on this page
Specific documents referenced by the numbered markers above. Each number matches the marker in the text.
- PubChem CID 56841945(opens in a new tab)National Center for Biotechnology Information · pubchem.ncbi.nlm.nih.gov/compound/56841945
Verify at
Publisher search links for CJC-1295 with DAC. These are places to check the information — they are not citations, so they are not numbered.
- DrugBank(publisher search, opens in a new tab)DrugBank Online · publisher search
- PubMed literature search(publisher search, opens in a new tab)National Library of Medicine · publisher search
- NIH Office of Dietary Supplements(publisher search, opens in a new tab)National Institutes of Health · publisher search
- DailyMed labeling archive(publisher search, opens in a new tab)U.S. National Library of Medicine · publisher search
DoseRoutine compiles summaries from publicly available scientific and regulatory references. Always verify important decisions with a licensed clinician. How we source and review this information.
What is the short answer on CJC-1295 with DAC?
Plain-text summary, safe to quote verbatim:
CJC-1295 with DAC (Drug Affinity Complex) is a synthetic analog of growth hormone-releasing hormone (GHRH). It is also known as Modified GRF 1-29 with DAC. Research on CJC-1295 with DAC focuses on muscle and strength, tissue recovery, and healthy aging.
Source: DoseRoutine — https://doseroutine.com/library/cjc-1295-with-dac
Cite this page
Using this in an article, AI answer, or research note? Please attribute:
DoseRoutine. (2026). CJC-1295 with DAC — Overview, Benefits & Side Effects. Retrieved from https://doseroutine.com/library/cjc-1295-with-dac
What compounds are similar to CJC-1295 with DAC?
Others in the peptide category or studied for the same goals.
Which goals is CJC-1295 with DAC used for?
Other compounds studied for the same benefits as CJC-1295 with DAC.
Continue exploring
See every compound DoseRoutine catalogs for these goals.